Nanoformulation of siRNA silencing Bcl-2 gene and its implication in cancer therapy

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Molecular Biology

Background:

• Overexpression of the anti-apoptotic Bcl-2 gene is common in many cancers, hindering programmed cell death (apoptosis).
• Elevated Bcl-2 levels contribute to chemotherapy resistance and reduced apoptosis induction by therapeutic agents.
• Targeting Bcl-2 offers a strategy to restore apoptosis in cancer cells.

Purpose of the Study:

• To prepare poly(d,l-lactide-co-glycolide) (PLGA) nanoparticles for the delivery of small interfering RNA (siRNA).
• To utilize siRNA to silence the anti-apoptotic Bcl-2 gene in cancerous cells.
• To evaluate the efficacy of PLGA nanoparticles in delivering siRNA for gene silencing and tumor reduction.

Main Methods:

• The double emulsion solvent diffusion (DESE) method was employed to create PLGA nanoparticles.
• Poly(d,l-lactide-co-glycolide) (PLGA) nanoparticles were loaded with small interfering RNA (siRNA).
• In vitro cell culture and in vivo studies were conducted to assess gene silencing and therapeutic effects.

Main Results:

• PLGA nanoparticles demonstrated effective binding and nuclease protection of siRNA.
• In vitro studies confirmed efficient silencing of the Bcl-2 gene in mammalian cancer cells.
• In vivo studies showed significant tumor volume reduction, indicating successful siRNA delivery and therapeutic efficacy.

Conclusions:

• PLGA nanoparticles are a viable delivery system for siRNA targeting the Bcl-2 gene.
• siRNA-loaded PLGA nanoparticles effectively inhibit Bcl-2 expression and reduce tumor growth.
• This approach holds potential for novel cancer treatment strategies by restoring apoptosis.